Congenital Antithrombin Deficiency
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OctapharmaAtenativ
Kyowa Hakko KirinKW-3357
Clinical Trials (2)
Total enrollment: 54 patients across 2 trials
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
Start: Jul 2022Est. completion: Jun 202638 patients
Phase 3Recruiting
A Study of KW-3357 in Congenital Antithrombin Deficiency
Start: Apr 2009Est. completion: Apr 201116 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 54 patients
2 companies competing in this space